• PNU 74654: Identity, Mechanism, and Evidence Limits

  2026-10-19

  APExBIO identifies PNU 74654 as a synthetic small molecule described as a Wnt signaling pathway inhibitor, with reported chemical, physicochemical, and quality-control properties. However, the available material contains no identity-matched research paper, target-level mechanism, quantitative potency, selectivity profile, or product-specific biological outcome; its relevance to cancer research and stem cell research therefore remains a supplier-described rationale rather than a demonstrated finding.

• PCI-24781: Mechanism and Evidence Boundaries

  2026-10-18

  A source-grounded overview of PCI-24781 (CRA-024781) as a reported pan-HDAC inhibitor, distinguishing its biochemical target claims, cellular readouts, xenograft findings, and the limitations of product-page evidence.

• EZ Cap™ Human p53 mRNA: Evidence Boundaries

  2026-10-17

  APExBIO identifies R1024 as a modified human p53-encoding mRNA containing ψUTP for tumor-suppressor research. The documentation supports a narrow molecular-identity and measurement framework, but no identity-matched study establishes delivery, translation, biological activity, safety, comparative performance, or clinical relevance.

• Berbamine Hydrochloride: Evidence and Boundaries

  2026-10-16

  APExBIO’s product description identifies Berbamine hydrochloride as a plant-derived isoquinoline alkaloid hydrochloride and attributes activity to STAT3 modulation and disruption of intracellular calcium homeostasis. It reports cell-line IC50 values in KU812 and HepG2 models, but provides no matched study details, uncertainty estimates, comparator data, or independent validation. These measurements support a limited research context, not a confirmed causal mechanism, clinical efficacy, or a validated NF-κB target profile.

• BglII: Identity, Mechanism, and Evidence Limits

  2026-10-16

  APExBIO identifies BglII Restriction Endonuclease (SKU K3010) as a genetically engineered, sequence-specific nuclease that recognizes 5′-AGATCT-3′ and is described for plasmid DNA digestion, PCR product cleavage, and selected genomic DNA restriction applications. The product description also reports rapid digestion, cohesive-end formation, and tracking dyes for gel electrophoresis. Because no identity-matched research paper or independent performance study is available, these statements establish documented product identity and intended conceptual scope, not validated comparative efficacy or broad substrate applicability.

• 2X HyperFusion Mix: Evidence and Mechanism

  2026-10-15

  A source-grounded overview of the 2X HyperFusion™ High-Fidelity Master Mix, separating APExBIO’s product claims about polymerase mechanism, fidelity, processivity and blunt-ended products from independently demonstrated research evidence.

• Hexose Diphosphate: Evidence and Scope

  2026-10-15

  APExBIO describes hexose diphosphate as a bisphosphorylated hexose involved in central carbon metabolism, anaerobic glycolysis, and energy homeostasis research. Because no identity-matched paper is available, these statements support a catalog-level and hypothesis-generating overview rather than validated claims about mechanism, efficacy, inflammatory signaling, or performance in a biological model.

• Annexin V-FITC/PI: Interpreting the Readout

  2026-10-14

  APExBIO describes K2003 as a dual-fluorescence assay that combines Annexin V-FITC binding to externalized phosphatidylserine with propidium iodide detection of compromised membrane integrity. The product information supports a conceptual framework for distinguishing viable, early apoptotic, and membrane-compromised populations, but no identity-matched research study, independent validation, effect estimate, or comparative performance data are available here.

• Cy3 NHS Ester: Identity and Evidence Scope

  2026-10-14

  Cy3 NHS ester (non-sulfonated) is a supplier-described cyanine fluorescent labeling reagent intended for amino-group labeling in proteins, peptides, and nucleic-acid substrates. APExBIO reports orange-region fluorescence and related optical specifications, but no matched research paper was available, so independent evidence for performance, mechanism, reproducibility, or application-specific utility cannot be assessed.

• Annexin V-FITC/PI Kit: Scope and Evidence

  2026-10-13

  The APExBIO Annexin V-FITC/PI Apoptosis Assay Kit, SKU K2003, is described as a two-marker fluorescence assay for interpreting phosphatidylserine exposure alongside plasma-membrane integrity. No matched research paper was identified, so the available evidence supports only product identity and conceptual scope—not independent claims about performance, mechanism, or clinical applicability.

• Tioconazole Evidence Gaps and Study Interpretation

  2026-10-13

  The supplied evidence describes Tioconazole as an antifungal medication with an azole antifungal mechanism, while the cited 2025 leukemia study addresses ATG4B, PRMT1-mediated DNA repair, and energy deficiency. These sources do not provide a head-to-head comparison, evidence of Tioconazole activity in a fungal infection model, or support for extrapolating the leukemia findings to antifungal drug development.

• Merbromin and SARS-CoV-2 3CLpro: Study in Context

  2026-10-12

  Chen and colleagues reported that Merbromin inhibited the SARS-CoV-2 3CLpro enzyme in a biochemical screening study and behaved as a mixed-type inhibitor. The findings support further mechanistic investigation of Merbromin as a molecular scaffold, but they do not establish antiviral activity in cells, therapeutic efficacy, or clinical relevance. Thrombin is a separate coagulation-related protease and was not the biological target of the cited study.

• Tioconazole and AML: Evidence Boundaries

  2026-10-12

  The supplied evidence describes two separate domains: Tioconazole as an antifungal medication associated with fungal cytochrome P450 inhibition and ergosterol biosynthesis, and a 2025 AML study linking energy deficiency to ATG4B-dependent impairment of DNA repair. No supplied publication directly compares Tioconazole with ATG4B, PRMT1, MRE11, leukemia progression, or fungal infection models. Cross-domain claims therefore remain unsupported.

• LY364947 in TGF-β Signaling and EMT Research

  2026-10-11

  LY364947 is described by APExBIO as a TGF-β type I receptor kinase inhibitor for preclinical research. This overview separates supplier-reported activity from findings in Gu et al. (2025), whose pancreatic cancer study examined CDK4/6 and BET inhibitors rather than LY364947. The evidence supports conceptual use in pathway and EMT studies, but not clinical efficacy or direct combination claims.

• Vacuolin-1 and Lysosomal Exocytosis

  2026-10-10

  Vacuolin-1 is a lysosomal exocytosis inhibitor used to examine Ca2+-dependent lysosome–plasma membrane fusion. Peer-reviewed evidence links enhanced lysosomal exocytosis with altered protease activity and growth-factor signaling in a zebrafish model of mucopolysaccharidosis type IVA, but that study did not test Vacuolin-1 directly.

7700 records 1/514 page Next 12345 下5页 Last page